Ivan Barilar
Overview
Explore the profile of Ivan Barilar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
436
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Diricks M, Maurer F, Dreyer V, Barilar I, Utpatel C, Merker M, et al.
Genome Med
. 2025 Mar;
17(1):19.
PMID: 40038805
Background: Non-tuberculous mycobacteria (NTM) are a diverse group of environmental bacteria that are increasingly associated with human infections and difficult to treat. Plasmids, which might carry resistance and virulence factors,...
2.
Wang Q, Barilar I, Minin V, Modongo C, Moonan P, Finlay A, et al.
medRxiv
. 2025 Jan;
PMID: 39763523
Tuberculosis epidemics have traditionally been conceptualized as arising from a single uniform pathogen. However, -complex (Mtbc), the pathogen causing tuberculosis in humans, encompasses multiple lineages exhibiting genetic and phenotypic diversity...
3.
Baker C, Barilar I, de Araujo L, Parker D, Fornace K, Moonan P, et al.
medRxiv
. 2024 Dec;
PMID: 39677427
Background: The integration of genomic and geospatial data into infectious disease transmission analyses typically includes residential locations and excludes other activity spaces where transmission may occur ( work, school, or...
4.
Dreyer V, Sonnenkalb L, Diricks M, Utpatel C, Barilar I, Mohr V, et al.
Methods Mol Biol
. 2024 Jul;
2833:195-210.
PMID: 38949712
Whole genome sequencing of Mycobacterium tuberculosis complex (MTBC) isolates has been shown to provide accurate predictions for resistance and susceptibility for many first- and second-line anti-tuberculosis drugs. However, bioinformatic pipelines...
5.
Mohr V, Sonnenkalb L, Utpatel C, Barilar I, Diricks M, Dreyer V, et al.
Methods Mol Biol
. 2024 Jul;
2833:185-193.
PMID: 38949711
Whole genome sequencing (WGS) is becoming an important diagnostic tool for antimicrobial susceptibility testing of Mycobacterium tuberculosis complex (MTBC) isolates in many countries. WGS protocols usually start with the preparation...
6.
Blankson H, Kamara R, Barilar I, Andres S, Conteh O, Dallenga T, et al.
Microbiol Spectr
. 2024 Jan;
12(3):e0240523.
PMID: 38289066
Importance: A substantial proportion of MDR-TB strains in Sierra Leone were resistant against all first line drugs; however this makes the all-oral-six-month BPaLM regimen or other 6-9 months all oral...
7.
Challenging the gold standard: the limitations of molecular assays for detection of heteroresistance
Danchuk S, Solomon O, Kohl T, Dreyer V, Barilar I, Utpatel C, et al.
Thorax
. 2024 Jan;
79(7):670-675.
PMID: 38286614
Objectives: Heteroresistant infections are defined as infections in which a mixture of drug-resistant and drug-susceptible populations are present. In (), heteroresistance poses a challenge in diagnosis and has been linked...
8.
Barilar I, Fernando T, Utpatel C, Abujate C, Madeira C, Jose B, et al.
Lancet Infect Dis
. 2023 Nov;
24(3):297-307.
PMID: 37956677
Background: In 2021, an estimated 4800 people developed rifampicin-resistant tuberculosis in Mozambique, 75% of which went undiagnosed. Detailed molecular data on rifampicin-resistant and multidrug-resistant (MDR) tuberculosis are not available. Here,...
9.
Modongo C, Barilar I, Wang Q, Molefi T, Makhondo T, Niemann S, et al.
Emerg Infect Dis
. 2023 Oct;
29(11):2403-2406.
PMID: 37877680
GeneXpert MTB/RIF, a tool widely used for diagnosing tuberculosis, has limitations for detecting rifampin resistance in certain variants. We report transmission of a pre-extensively drug-resistant variant in Botswana that went...
10.
Lundeberg E, Andersson V, Wijkander M, Groenheit R, Mansjo M, Werngren J, et al.
Microbiol Spectr
. 2023 Sep;
:e0178123.
PMID: 37737628
As meropenem-clavulanic acid is recommended for the treatment of drug-resistant tuberculosis, the repurposing of new carbapenem combinations may provide new treatment options, including oral alternatives. Therefore, we studied the activities...